DNA-PK participates in pre-rRNA biogenesis independent of DNA double-strand break repair

Peng Li,Xiaochen Gai,Qilin Li,Qianqian Yang,Xiaochun Yu

DOI: https://doi.org/10.1093/nar/gkae316

IF: 14.9

2024-04-30

Nucleic Acids Research

Abstract:Although DNA-PK inhibitors (DNA-PK-i) have been applied in clinical trials for cancer treatment, the biomarkers and mechanism of action of DNA-PK-i in tumor cell suppression remain unclear. Here, we observed that a low dose of DNA-PK-i and PARP inhibitor (PARP-i) synthetically suppresses BRCA-deficient tumor cells without inducing DNA double-strand breaks (DSBs). Instead, we found that a fraction of DNA-PK localized inside of nucleoli, where we did not observe obvious DSBs. Moreover, the Ku proteins recognize pre-rRNA that facilitates DNA-PKcs autophosphorylation independent of DNA damage. Ribosomal proteins are also phosphorylated by DNA-PK, which regulates pre-rRNA biogenesis. In addition, DNA-PK-i acts together with PARP-i to suppress pre-rRNA biogenesis and tumor cell growth. Collectively, our studies reveal a DNA damage repair-independent role of DNA-PK-i in tumor suppression.

biochemistry & molecular biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the inhibitory mechanism of the combined use of DNA - PK inhibitors (DNA - PK - i) and PARP inhibitors (PARP - i) on BRCA - deficient tumor cells, especially whether this combined treatment can inhibit the growth of tumor cells without causing DNA double - strand breaks (DSBs).

Specifically, the researchers focused on the following aspects:

1. **Efficacy of combined treatment**: When low - dose DNA - PK - i or PARP - i was used alone, the growth - inhibitory effect on BRCA - deficient tumor cells (such as HCC1937 cells) was not obvious. However, when these two inhibitors were used in combination, they could significantly inhibit the growth of these cells even at very low doses.

2. **DNA damage response**: The researchers found that although the combined treatment could inhibit the growth of BRCA - deficient tumor cells, this treatment did not induce obvious DNA double - strand breaks (DSBs) in the cells. In addition, no alternative markers of DSBs, such as the formation of phosphorylated ATM and 53BP1 foci, were observed.

3. **Nucleolar localization of DNA - PK**: The researchers found that a part of DNA - PK was located in the nucleolus rather than at the DSBs sites. This indicates that DNA - PK may be involved in other biological processes in the nucleolus, not just DNA damage repair.

4. **pre - rRNA biogenesis**: Further research has shown that DNA - PK regulates the biogenesis of pre - rRNA by phosphorylating ribosomal proteins. The combined use of DNA - PK - i and PARP - i will inhibit the biogenesis of pre - rRNA, thus affecting the growth of tumor cells.

In summary, this paper aims to reveal a new mechanism by which the combined treatment of DNA - PK - i and PARP - i inhibits the growth of BRCA - deficient tumor cells by affecting the biogenesis of pre - rRNA without relying on DNA damage repair.